echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Potential curative therapy for hepatitis B has entered a critical development stage, and the virus can continue to be suppressed after the drug is stopped

    Potential curative therapy for hepatitis B has entered a critical development stage, and the virus can continue to be suppressed after the drug is stopped

    • Last Update: 2021-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On November 3, 2021, Antios Therapeutics announced the completion of a US$75 million B-1 round of financing to develop innovative therapies for functional cures of chronic hepatitis B virus (HBV) infection


    ATI-2173 is a new type of oral ASPIN molecule designed to deliver the 5'-monophosphate of clevudine to the liver


    So far, preclinical data of ATI-2173 as a single agent or in combination with tenofovir disoproxil fumarate (TDF) show that it has the ability to continuously inhibit HBV DNA levels


    Reference materials:

    [1] Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.